╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Received radiation to more than 10% of bone        │ Received radiation to more than 10% of bone.       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of an investigational agent within 30 days     │ Use of an investigational agent within 30 days.    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Received more than one primary chemotherapy        │ Received more than one primary chemotherapy        │
│ regimen                                            │ regimen.                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ at least 4 weeks since last surgery or radiation   │ No Match                                           │
│ therapy                                            │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ ECOG performance status of 0,1, or 2               │ ECOG performance status of 0,1, or 2.              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ must have minimum age of 18 Years                  │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concomitant or previous malignancies with the      │ Concomitant or previous malignancies with the      │
│ exception of adequately treated basal cell or      │ exception of adequately treated basal cell or      │
│ squamous cell skin cancer, in situ cervical        │ squamous cell skin cancer, in situ cervical        │
│ cancer, incidental carcinoid, or other cancer from │ cancer, incidental carcinoid, or other cancer from │
│ which the patient has been disease free for 5      │ which the patient has been disease free for 5      │
│ years                                              │ years.                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ must have had a treatment-free interval of greater │ No Match                                           │
│ than 6 months following response to platinum       │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active uncontrolled infection requiring            │ Active uncontrolled infection requiring            │
│ antibiotics                                        │ antibiotics.                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have had one prior platinum-based chemotherapy     │ Have had one prior platinum-based chemotherapy     │
│ regimen for the treatment of primary disease.      │ regimen for the treatment of primary disease.      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant or lactating                              │ Pregnant or lactating.                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of child-bearing potential that do not       │ Women of child-bearing potential that do not       │
│ practice adequate contraception                    │ practice adequate contraception.                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hypersensitivity to camptothecin or nucleoside     │ Hypersensitivity to camptothecin or nucleoside     │
│ analogues                                          │ analogues.                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ must be FEMALE                                     │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Prior treatment with topotecan or gemcitabine      │ Prior treatment with topotecan or gemcitabine.     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concurrent severe medical problems unrelated to    │ Concurrent severe medical problems unrelated to    │
│ the malignancy which would limit full compliance   │ the malignancy which would limit full compliance   │
│ with the study                                     │ with the study.                                    │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛